VRG Therapeutics Announces Monthly Dosing for Its Lead Program Targeting Kv1.3 for the Treatment of Atopic Dermatitis and Other Chronic Inflammatory Diseases
Team
May 14, 2024
By VRG Therapeutics
First stage gating meeting of the year
Combi-X
VRG-145
April 17, 2024
By VRG Therapeutics
VRG Therapeutics Advances VRG-145
Infrastructure
April 11, 2024
By VRG Therapeutics
VRG Tx Launches Its In Vivo R&D Facility!
Kv1.3
March 12, 2024
By VRG Therapeutics
Publication - Journal of Biological Chemistry
Kv1.3
AI
February 20, 2024
By VRG Therapeutics
Press release: Experimental verification of our AI-powered drug discovery
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.